GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » Net Income Including Noncontrolling Interests

Bright Minds Biosciences (XCNQ:DRUG) Net Income Including Noncontrolling Interests : C$-6.72 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Bright Minds Biosciences's Net Income Including Noncontrolling Interests for the three months ended in Dec. 2023 was C$-1.68 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was C$-6.72 Mil.


Bright Minds Biosciences Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Bright Minds Biosciences's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Net Income Including Noncontrolling Interests Chart

Bright Minds Biosciences Annual Data
Trend Sep20 Sep21 Sep22 Sep23
Net Income Including Noncontrolling Interests
-0.48 -8.65 -14.97 -7.37

Bright Minds Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.34 -2.05 -1.46 -1.53 -1.68

Bright Minds Biosciences Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-6.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bright Minds Biosciences Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Bright Minds Biosciences (XCNQ:DRUG) Business Description

Industry
Traded in Other Exchanges
Address
19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Bright Minds Biosciences (XCNQ:DRUG) Headlines

From GuruFocus